Cargando…
The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial
AIMS: Iron deficiency is common in heart failure with reduced ejection fraction (HFrEF) and negatively affects cardiac function and structure. The study the effect of ferric carboxymaltose (FCM) on cardiac reverse remodelling and contractile status in HFrEF. METHODS AND RESULTS: Symptomatic HFrEF pa...
Autores principales: | Martens, Pieter, Dupont, Matthias, Dauw, Jeroen, Nijst, Petra, Herbots, Lieven, Dendale, Paul, Vandervoort, Pieter, Bruckers, Liesbeth, Tang, Wai Hong Wilson, Mullens, Wilfried |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691806/ https://www.ncbi.nlm.nih.gov/pubmed/34185066 http://dx.doi.org/10.1093/eurheartj/ehab411 |
Ejemplares similares
-
Rationale and design of the IRON‐CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy
por: Martens, Pieter, et al.
Publicado: (2019) -
The impact of intravenous ferric carboxymaltose on reverse electrical remodeling following cardiac resynchronization therapy
por: Bozcali, E, et al.
Publicado: (2023) -
Upgrade of right ventricular pacing to cardiac resynchronization therapy in heart failure: a randomized trial
por: Merkely, Béla, et al.
Publicado: (2023) -
Lateral Gene Transfer Shapes the Distribution of RuBisCO among Candidate Phyla Radiation Bacteria and DPANN Archaea
por: Jaffe, Alexander L, et al.
Publicado: (2019) -
Patiromer for the management of hyperkalemia in heart failure with reduced
ejection fraction: the DIAMOND trial( )
por: Butler, Javed, et al.
Publicado: (2022)